Skip to main content
. Author manuscript; available in PMC: 2014 Mar 25.
Published in final edited form as: Behav Brain Res. 2012 Apr 9;232(1):98–113. doi: 10.1016/j.bbr.2012.04.001

Fig. 3.

Fig. 3

Effects of Gö6976 (a co-inhibitor of PKCα and -β), hispidin (a PKCβ inhibitor), PKCζ pseudosubstrate inhibitor (a PKCζ inhibitor), and rottlerin (a PKCδ inhibitor) on locomotor activity (A) and rota-rod performance (B) 3 d and 14 d after the final methamphetamine (MA) treatment. Sal + Sal = saline (i.c.v.) + saline (i.p.); Vehicle (10% DMSO) = Veh. Veh + Sal = vehicle (i.c.v.) + saline (i.p.). Sal + MA = saline (i.c.v.) + MA (i.p.). Veh + MA = vehicle (i.c.v.) + MA (i.p.). Gö 1.0 or Gö 2.0 = Gö6976 at a dose of 1.0 or 2.0 μg, i.c.v.; His 3.0 = hispidin at a dose of 3.0 μg, i.c.v.; PKCζ PS 1.5 or PKCζ PS 3.0 = PKCζ pseudosubstrate inhibitor at a dose of 1.5 or 3.0 μg, i.c.v.; Rott 1.5 or Rott 3.0 = rottlerin at a dose of 1.5 or 3.0 μg, i.c.v.. Each value is the mean ± S.E.M. of 12–18 animals. *P < 0.01 vs. Sal + Sal. #P < 0.05, ##P < 0.01 vs. Veh + MA (one-way ANOVA followed by Fisher's PLSD test).